WGRX Research | Milton Maxwell

WGRX

Wellgistics Health, Inc.

0.5400

-0.0400-6.9%

Dec 16, 4:00:01 PM EST

Upcoming Earnings

Report date

≈ -/-

Earnings Call Transcripts

This Quarter (Q1 '26)

No earnings call transcript available yet

Last Quarter (Q4 '25)

No earnings call transcript available

Key Stats

Market Cap

55.24M

P/E (TTM)

Basic EPS (TTM)

-1.28

Dividend Yield

Recent Filings

10-K

FY2025 results

3/20/26Mar 20, 2026

Wellgistics Health posted FY2025 revenues of $23.3M, up from $18.1M in FY2024, driven by full-year contributions from its pharmacy and wholesale segments following 2024 acquisitions—yet Q4 momentum stalled amid liquidity squeezes that hiked inventory costs and forced a $6M aged-stock write-off, flipping gross profit to a $6.4M loss (down from $1.8M profit). Margins cratered to -27.5% as procurement delays curbed scale; operating loss exploded to $93.7M on $54.8M stock comp and $12.6M goodwill/intangible impairments. Debt swelled to $23.5M by year-end, with $10.9M current; free cash flow not disclosed. No 2026 guidance issued. Integration risks from recent buys threaten quarterly traction.

8-K

EBV revenue deal signed

3/11/26Mar 11, 2026

Wellgistics Health inked a 36-month revenue share deal with Kare PharmTech on March 6, 2026, to commercialize KARE Verify eligibility verification through its pharmacy network. Net revenues split 50/50. Preferred EBV pricing rolls out immediately via EinsteinRx, priming PharmacyChain integration. Revenue to kick in Q2 2026.

8-K

Launches Forzet for GLP-1 muscle loss

3/9/26Mar 9, 2026

Wellgistics Health launched Forzet, a medical food targeting muscle loss from GLP-1 agonists like Ozempic, on March 9, 2026. The company eyes the GLP-1 market's growth from $70B in 2025 to $201B in 2030. Forzet rolls out via its pharmacy network and EinsteinRx pop-ups. Launch taps unmet needs. Forward-looking risks include market acceptance.

8-K

Settles $10.7M debt via stock

2/13/26Feb 13, 2026

Wellgistics Health settled $10.7M in liabilities with Silverback Capital by issuing common stock at fixed prices from $0.25/share, court-approved February 4, 2026, plus 400,000 extra shares for fees. First $2.25M tranche locked at $0.25/share via February 9 amendment. Shares issued unregistered under Section 3(a)(10). Company also tapped Gerald Commissiong as consulting Chief Business Officer.

8-K

NFL Alumni Health partnership

2/9/26Feb 9, 2026

Wellgistics Health inked a deal with NFL Alumni Health on February 3, 2026, to roll out EinsteinRx AI and PharmacyChain smart contracts for better health outcomes in mental health, weight loss, sleep apnea, cardiometabolic disease, pain management, and Long COVID—starting with ex-NFL players, then rural communities via its 6,500-pharmacy network. Gary Herman joined the board as independent director and Audit Committee chair effective February 4. NFL ambassadors boost local pharmacy engagement. Forward-looking plans hinge on execution risks.

About

Wellgistics Health, Inc. engages in the wholesale and distribution of pharmaceutical products to pharmaceutical manufacturers and independent retail pharmacies in the United States. The company distributes generic and branded pharmaceuticals, as well as over-the-counter healthcare and consumer products. It also offers third-party logistics services that include warehousing, inventory management, pick and pack, and shipping to small and mid-size pharmaceutical manufacturers. It also operates DelivMeds platform that serves as a pharmaceutical hub to facilitate the transfer of prescriptions and provide backend clinical concierge services to a network of independent pharmacies; and operates a retail community specialty. The company was formerly known as Danam Health, Inc. and changed its name to Wellgistics Health, Inc. in October 2024. Wellgistics Health, Inc. was incorporated in 2022 and is based in Tampa, Florida.

CEO

Mr. Prashant Patel M.Sc., R.Ph.

IPO

2/21/2025

Website

https://www.wellgisticshealth.com

Sector

Healthcare

Industry

Pharmaceutical Retailers